Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
Cytox Appoints New CCO
November 6, 2018
Oxford and Manchester, UK – Cytox, a precision medicine company focused on developing solutions to identify individuals most at risk for developing Alzheimer's disease and dementia, today announced the appointment of Antony Hill as Chief Commercial Officer.
“We are pleased to welcome Tony Hill to the Cytox team,’ commented Cytox CEO, Dr Richard Pither, "He joins us at a very exciting time for Cytox. This year we announced several important new collaborations and funding from Innovate UK, and presented results on our recent advancements at all the major conferences, including how we identify Alzheimer’s disease risk in ApoE3 homozygote individuals, and also identify those individuals most likely to progress from mild cognitive impairment to Alzheimer’s.
“Tony has been involved in the diagnostics and molecular life sciences industry for 30 years, with senior roles in sales and marketing in international diagnostics and molecular life science companies including TwistDx Ltd (part of Abbott Diagnostics), Diasorin Molecular, Innogenetics and Sigma-Aldrich. He will greatly strengthen our management team and enable us to progress our partnerships and develop our clinical products.”